Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-04-05
2011-04-05
Rawlings, Stephen L (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S023500, C530S350000, C530S387100, C435S320100, C435S325000
Reexamination Certificate
active
07919606
ABSTRACT:
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
REFERENCES:
patent: 3957362 (1976-05-01), Mancini et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5382510 (1995-01-01), Levine et al.
patent: 5436265 (1995-07-01), Black et al.
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5693762 (1997-12-01), Queen
patent: 5712374 (1998-01-01), Kuntsmann et al.
patent: 5714350 (1998-02-01), Co
patent: 5714586 (1998-02-01), Kunstmann et al.
patent: 5789554 (1998-08-01), Leung
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6183744 (2001-02-01), Goldenberg
patent: 6777390 (2004-08-01), Matthiessen
patent: 7012135 (2006-03-01), Athwal et al.
patent: 7115723 (2006-10-01), Hong et al.
patent: 7129053 (2006-10-01), Reiter
patent: 7147851 (2006-12-01), Ponath
patent: 7355011 (2008-04-01), Popplewell et al.
patent: 2002/0141990 (2002-10-01), Deen et al.
patent: 2005/0095238 (2005-05-01), Brettman
patent: 2007/0172920 (2007-07-01), Leung
patent: 0239400 (1987-09-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 96/04925 (1996-02-01), None
patent: WO 96/05306 (1996-02-01), None
patent: WO 98/41641 (1998-09-01), None
patent: WO 98/42378 (1998-10-01), None
patent: WO 98-56418 (1998-12-01), None
patent: WO 00/74718 (2000-12-01), None
patent: WO 03/092623 (2003-11-01), None
Mariuzza et al. (Annu. Rev. Biophys. Biophys. Chem. 1987; 16: 139-159).
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79: p. 1979-1983).
MacCallum et al. (J. Mol. Biol. Oct. 11, 1996; 262 (5): 732-745).
Holm et al. (Mol. Immunol. Feb. 2007; 44 (6): 1075-1084).
William E. Paul, “Fundamental Immunology”, 3rded. (textbook), pp. 292-295, 1993.
Riechmann, Lutz, et al., “Reshaping human antibodies for therapy”, Nature, vol. 332, pp. 323-327, 1988.
Rudikoff, Stuart, et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl. Acad. Sci. USA, vol. 79, pp. 1979-1983, 1982.
Verhoeyen, Martine, et al., “Reshaping human antibodies: Grafting an antilysozyme activity”, Science, vol. 239, pp. 1534-1536, 1988.
Hinman et al., “Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics”, Cancer Res., vol. 53: 3336-3342 1993,.
Hamann et al., “An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker”, Bioconjug. Chem., vol. 13: 40-45., 2002,.
Jendreyko et al., “Antitumor activity of Calicheamicin theta, Doxorubicin and anti-CD19 immunoconjugates in a human pre-B ALL cell line”, Blood, vol. 98: 105a (Abstract #440) 2001.
Siegel et al., “Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry”, Anal. Chem., vol. 69: 2716-2726, 1997.
Ghetie et al., “The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin”,Blood, vol. 80(9): 2315-2320 1992.
Newton, et al., “Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma”, Blood vol. 97(2): 528-535, 2001.
Maloney et al., “IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-hodgkin's lymphoma”, Blood vol. 90(6); 2188-2195, 1997.
Gura, “Systems for identifying new drugs are often faulty”, Science vol. 278: 1041-1042, 1997.
Saijo “What are the reasons for negative phase III trails of molecular-target-based drugs”, Cancer Sci. vol. 95(10): 772-776, 1994.
Yelton, et al., “Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis” The Journal of Immunology. vol. 155, 1994-2004, 1995.
Benhar et al., “Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivation” Bioconjugate Chem., Vo. 5: 321-326 (abstract only)., www.theratears.com
utrition.htm (2003) 4pp, 1994.
Browning, et al., “B cells move to centre stage: novel opportunities for autoimmune disease treatment”, Nature Rev. Drug Discovery., vol. 5: 564-576, 2006.
Carnahan, et al., “Epratuzumab, a humanized nomoclonal antibody targeting CD22: characterization of in vitro properties”, Clinical Cancer Research, 9 suppl.: 3982s-3990s, 2003.
Dijoseph et al., “Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22” Cancer Immunology Immunother, vol. 54: 11-24 2005.
Dijoseph et al., “Antibody-targeted chemotherapy with CMC-544: a CD22-targed immunoconjugte of calicheamicin for the treatment of B-lymphoid malignancies” Blood, vol. 103: 1807-1814, 2004.
Leung et al., “Construction and characterization of a humanized iternalizing, B-cell (CD22)-specific leukemia/lymphoma antibody, LL2,” Mol. Immunol., vol. 32: 1413-1427, 1995.
Leung et al., “Effect of Vk framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site” Intl. J. Cancer, vol. 60: 534-538, 1995.
Vaughan, et al., “Human antibodies by design”, Nature Biotech, vol. 16: 535-539, 1998.
Van Rossenberg, et al., “A structure-function study of ligand recognition by CD22 beta” J. Bio: Chem., vol. 276: 12967-12973, 2001.
Vose, J.M.., “Therapeutic uses of MAbs directed against CD20” Cytotherapy, vol. 2:455-461, 2000.
Riechmann et al., “Reshaping human antibodies for therapy”, Nature, vol. 332: 323-327, 1988.
Verhoeyen et al., “Reshaping human antibodies: Grafting an antilysozyme activity”, Science, Vol. 239: 1534-1536, 1988.
Ladyman Heather Margaret
Popplewell Andrew George
Tickle Simon Peter
Cozen O'Connor
Duffy Brad
Rawlings Stephen L
UCB Pharma S.A.
LandOfFree
Biological products does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biological products, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biological products will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2632009